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Abstract 
Aims: To investigate whether BM-573 (N-tert-butyl-N'-[2-(4'-methylphenylamino)-5-nitro-
benzenesulfonyl]urea), an original combined thromboxane A2 synthase inhibitor and receptor antagonist, 
prevents reperfusion injury in acutely ischemic pigs. Methods: Twelve animals were randomly divided in two 
groups: a control group (n = 6) intravenously infused with vehicle, and a BM-573-treated group (n = 6) infused 
with BM-573 (10 mgkg-1 h-1). In both groups, the left anterior descending (LAD) coronary artery was occluded 
for 60 min and reperfused for 240 min. Either vehicle or BM-573 was infused 30 min before LAD occlusion and 
throughout the experiment. Platelet aggregation induced by arachidonic acid ex vivo measured was prevented by 
BM-573. Results:  In both groups, LAD occlusion decreased cardiac output, ejection fraction, slope of stroke 
work—end-diastolic volume relationship, and induced end-systolic pressure-volume relationship (ESPVR) 
rightward shift, while left ventricular afterload increased. Ventriculo-arterial coupling and mechanical efficiency 
decreased. In both groups, reperfusion further decreased cardiac output and ejection fraction, while ESPVR 
displayed a further rightward shift. Ventriculo-arterial coupling and mechanical efficiency remained impaired. 
Area at risk, evidenced with Evans blue, was 33.2 ± 3.4% of the LV mass (LVM) in both groups, and mean 
infarct size, revealed by triphenyltetrazolium chloride (TTC), was 27.3 ± 2.6% of the LVM in the BM-573-
treated group (NS). Histological examination and immunohistochemical identification of desmin revealed 
necrosis in the anteroseptal region similar in both groups, while myocardial ATP dosages and electron 
microscopy also showed that BM-573 had no cardioprotective effect. Conclusions: These data suggest that BM-
573 failed to prevent reperfusion injury in acutely ischemic pigs. 
Keywords:  Thromboxane synthase inhibitor; Thromboxane receptor antagonist; Myocardial ischemia; 
Reperfusion injury; Contractile function; Hemodynamics; Pig 
 
1.  Introduction 
Myocardial ischemia in the clinical setting is usually a consequence of a thrombotic occlusion of a coronary 
artery at the site of a ruptured atherosclerotic plaque. Prompt re-establishment of coronary flow following 
coronary occlusion is mandatory for the preservation of myocardial tissue. The establishment of reperfusion, 
originally by coronary thrombolysis and subsequently also by percutaneous coronary interventions, was a major 
improvement in the management of patients with myocardial infarction and rapidly gained wide acceptance          
[1-3]. 
A short a time as possible between coronary occlusion and reperfusion is mandatory for successful salvage of 
myocardial tissue, so as to decrease post-myocardial infarction mortality [4]. However, paradoxically, 
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myocardial damage is still observed even after early successful reperfusion. This and other observations led to 
the concept that, although reperfusion is needed for myocardial salvage, it may also trigger a further series of 
harmful events which add to myocardial injury. That part of myocardial injury and the clinical manifestations 
specifically triggered by reperfusion have been labelled "ischemia reperfusion-induced injury" [5,6]. It has been 
suggested that the impact of reperfusion plays a key role in accelerating the expression of irreversible myocardial 
damage caused by ischemia. 
Many factors contribute to the reperfusion injury characterised by cell death which not only occurs through 
necrosis. Generation of reactive oxygen species, including the superoxide anion, hydrogen peroxide and 
hydroxyl radicals are involved since they would trigger cardiac cell death through apoptotic mechanisms [7]. 
Intra-cellular calcium overload, accumulation, activation and infiltration of neutrophils releasing lysosomial 
enzymes and arachidonic acid products, endothelial dysfunction leading to a compromised microvascular 
nutritional blood flow (the "no-reflow" phenomenon) and activation of the renin-angiotensin system are other 
possibilities [8-10]. Some of these mechanisms are possibly interrelated and act together in the creation of 
reperfusion injury. On the basis of the possible multiple physiological mechanisms that are involved, a large 
number of pharmacological agents have been studied with the overall objective of reducing final infarct size. 
Among compounds tested are hydroxyl radical scavengers, antioxidants, beta-blockers, calcium antagonists, 
inhibitors of the renin-angiotensin system, and thromboxane receptors antagonists. 
It is well established that thromboxane A2 (TXA2), abnormally released during myocardial ischemia and 
reperfusion, in humans [11,12] and in animal models [13-15], mediates several pathophysiological states and 
events due to its biological activities as platelet aggregation, constriction of vascular smooth muscles, leukocyte 
chemotaxis, smooth muscle cells proliferation,…Consequently, blockade of TXA2 receptor with antagonists 
and/or inhibit TXA2 synthase with specific inhibitors could protect cardiac cells against deleterious effects of 
ischemia, but this remains a matter of debate as several studies have yielded contradictory results for TXA2 
receptor antagonists. Indeed, it has been demonstrated that such compounds were able to reduce the severity of 
myocardial infarction [15,16], while other studies failed to observe such protective effects [17,18]. 
Therefore, the aim of the present work was to determine whether BM-573 (N-tertbutyl-N'-[2-(4'-
methylphenylamino)-5-nitro-benzenesulfonyl]urea), an original non-carboxylic combined TXA2 synthase 
inhibitor and TXA2 receptor antagonist [19-21], would be able to prevent or to decrease ischemia-reperfusion 
injury in pigs suffering from 60 min ischemia followed by 240 min of reperfusion. Hemodynamic, 
histopathological, biochemical, and aggregrometric parameters were thoroughly evaluated. 
2.  Materials and methods 
2.1. Preparation 
All experimental procedures and protocols used in this investigation were reviewed and approved by the Ethics 
Committee of the Medical Faculty of the University of Liège. All procedures conformed to the Guiding 
Principles in the Care and Use of Animals of the American Physiological Society and were performed according 
to the Guide for the Care and Use of Laboratory Animals, [NIH publication no. 85-23, revised 1996]. 
Experiments were performed on 12 healthy pure pietran pigs of either sex (20-28 kg). The animals were 
premedicated with intramuscular administration of ketamine (20 mg kg-1) and diazepam (1 mg kg-1). Anesthesia 
was then induced and maintained by a continuous infusion of sufentanil (0.5 µg kg-1 h-1) and sodium 
pentobarbital (3 mg kg-1 h_1). Spontaneous movements were prevented by pancuronium bromide (0.1 mg kg-1 
h_1). After endotracheal intubation through a cervical tracheostomy, the pigs were connected to a volume-cycled 
ventilator (Evita 2, Dräger, Lübeck, Germany) set to deliver a tidal volume of 15 ml kg-1 at a respiratory rate of 
20 min-1. End-tidal pCO2 measurements (Capnomac, Datex, Helsinki, Finland) were used to monitor the 
adequacy of ventilation. Respiratory settings were adjusted to maintain end-tidal pCO2 in the range of 35-40 
Torr (4.67-5.33 kPa). Arterial oxygen saturation was closely monitored and maintained above 95% by adjusting 
the FiO2 as necessary. Central temperature was measured with a rectal probe and maintained at 37 °C by means 
of a heating blanket. A standard lead electrocardiogram was used for the monitoring of heart rate (HR). 
The chest was entered through median sternotomy, the pericardium was incised and sutured to the chest wall to 
form a cradle for the heart, and the root of the aorta was dissected clear of adherent fat and connective tissue. A 
combined conductance-micromanometer catheter (CD Leycom, Zoetermeer, The Netherlands) was inserted 
through the right carotid artery and advanced into the left ventricle. A micromanometer-tipped catheter (Sentron 
pressure measuring catheter, Cordis, Miami, FL, USA) was inserted through the right femoral artery and 
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advanced into the ascending aorta. A 14 mm diameter perivascular flow-probe (Transonic Systems Inc., Ithaca, 
NY, USA) was closely adjusted around the aorta 2 cm downstream to the aortic valve. The micromanometer-
tipped catheter was manipulated so that the pressure sensor was positioned just distal to the flow probe. Right 
atrial pressure was measured with a micromanometer-tipped catheter inserted into the cavity through the superior 
vena cava. A 6F Fogarty balloon catheter (Baxter Healthcare Corp., Oakland, CA, USA) was advanced into the 
inferior vena cava through a right femoral venotomy. Inflation of this balloon produced a titrable leftward shift in 
pressure-volume loops by reducing venous return. The jugular vein and the left femoral artery were cannulated 
for eventual drug administration and for blood samples analysis, respectively. 
A segment of the left anterior descending (LAD) coronary artery was isolated distal to the first diagonal branch 
for later application of a surgical clamp. An ultrasonic flow probe (Transonic Systems Inc., Ithaca, NY, USA) 
was placed around the LAD coronary artery three centimetres distal to the site of planned occlusion, to measure 
coronary artery blood flow. 
2.2. Hemodynamic measures 
To provide similar states of vascular filling, the animals were continuously infused with Ringer lactate (5 ml kg-1 
h_1), and, when necessary, with hydroxyethylstarch 6% to increase central venous pressure up to 6-7 mmHg over 
30 min. Baseline hemodynamic recordings were obtained thereafter including simultaneous measurements of 
aortic pressure and flow waveforms necessary to identify parameters of the three-element windkessel model. A 
first diagram of the left ventricular pressure-volume relationship was generated from volume and pressure 
measurements at baseline and during gradual decreases in preload by reducing venous return. The caval 
occlusion was limited to a few seconds in duration in order to avoid reflex responses. All measurements were 
taken immediately after the animal was briefly disconnected from the ventilator to sustain end-expiration. After 
deflation of the inferior vena cava balloon, the animals were allowed to rest for an additional 30 min. 
The animals were then randomly divided in two groups: a control group (n = 6) intravenously infused with 
vehicle (propylene glycol-NaCl 0.9%, 50:50), and a BM-573-treated group (n = 6) infused with BM-573               
(10 mg kg-1 h-1). The animals were then followed for 30 min, and hemodynamic measures were again obtained. 
Thereafter, the LAD coronary artery was occluded at the site of previous dissection. The occlusion was 
maintained for 60 min, period after which the LAD coronary artery was reperfused for 240 min in both groups. 
In all animals, hemodynamic measurements were obtained every 30 min throughout the experiment. Either 
vehicle or BM-573 was infused until the end of the experiment. 
2.2.1.  Data collection 
The conductance catheter was connected to a Sigma-5 signal-conditioner processor (CD Leycom, Zoetermeer, 
The Netherlands). Each ultrasonic flow-probe was connected to a flow-meter (HT 207, Transonic Systems Inc., 
Ithaca, NY, USA), and each micromanometer-tipped catheter to the appropriate monitor (Sentron pressure 
monitoring, Cordis, Miami, FL, USA). All analog signals and the ventricular pressure-volume loops were 
displayed on screen for continuous monitoring. The analog signals were continuously converted to digital form 
with an appropriate software (Codas, DataQ Instruments Inc., Akron, OH, USA) at a sampling frequency of 200 
Hz. 
2.2.2.  Data analysis 
2.2.2.1. Ventricular systolic function. Left ventricular volumes were inferred using the dual field conductance 
catheter technique [22]. Calibration of the conductance signal to obtain absolute volume was performed by the 
hypertonic saline method [22]. Therefore, a small volume (1-2 ml) of 10% NaCl solution was injected into the 
pulmonary artery during continuous data acquisition. 
LV contractile function was assessed by the end-systolic pressure-volume relation (ESPVR), and the preload 
recruitable stroke work (PRSW). 
The instantaneous pressure-volume relationship was considered in terms of a time-varying elastance E{t), 
defined by the following relationship: 
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where P(t) and V(t) are, respectively, the instantaneous ventricular pressure and volume, and Vd a correction 
term. End-systole was defined as the instant of time in the ejection phase at which E(t) reaches its maximum, 
Emax. It has been demonstrated that E(t) and Vd are insensitive to preload, at least within physiological ranges 
[23]. Preload was acutely reduced by inflating the inferior vena cava balloon catheter. 
Stroke work (SW) was calculated as the area enclosed within each pressure-volume loop and was plotted against 
end-diastolic volume (EDV; volume at the lower right corner of the loop) to generate the SW-EDV relation 
(preload recruitable stroke work, PRSW). 
2.2.2.2.  Myocardial energetics. Myocardial energetics was assessed by computation of pressure-volume area 
(PVA). In the time-varying elastance model of the ventricle, the total energy generated by each contraction is 
represented by the total area under the end-systolic pressure-volume relation line and the systolic segment of the 
pressure-volume loop, and above the end-diastolic pressure volume relation curve, and denoted by PVA (Fig. 3) 
[24]. PVA is the sum of SW (the energy that the ventricle delivers to the blood at ejection) and potential energy 
(PE; necessary to overcome the viscoelastic properties of the myocardium itself). It has been demonstrated that 
PVA was highly correlated with myocardial oxygen consumption [25]. 
Mechanical efficiency was defined as the SW/PVA ratio. 
2.2.2.3.  Arterial properties. Arterial properties were assessed from ascending aortic pressure and flow 
measurements and represented with a three-element windkessel model (WK3) [26]. In this model, the resistor R2 
represents the resistive properties of the systemic bed, which are considered to reside primarily in the arteriolar 
system. The capacitor C, placed in parallel with R2, represents the compliant properties of the large systemic 
arteries. The resistor R1 represents the characteristic impedance, which level depends prominently on the elastic 
properties of the proximal aorta. 
The values of R1, R2, and C were estimated by a method previously described [27]. Effective arterial elastance 
(Ea) was calculated according to the equation [28]: 
 
where Ts and Td are the systolic and diastolic time intervals, respectively. Ts was calculated, in the aortic pressure 
wave, as the time interval between the point just before the abrupt rise and the dicrotic notch. Ventriculo-arterial 
coupling was appreciated through the ratio Ees/Ea. 
2.3. Area at risk and infarct size quantifications 
Risk area and infarct area were delineated by a dual staining technique [20,29,30]. Immediately before the end of 
the experiment, 20 ml of Evans blue dye solution (0.1 g ml-1 in 50 mM phosphate buffered saline, pH 7.4) were 
injected into the jugular vein, to stain the non-ischemic area blue. The pig was then sacrificed with an 
intravenous injection of pentobarbital (100 mg kg-1). The heart was then rapidly harvested, rinsed with a cold 
isotonic saline solution and sectioned in five transverse slices (0.6 cm thick) from apex to base (S1-S5). The LV 
risk area, due to its anatomical dependence on the LAD coronary artery for blood flow, was identified in the 
anteroseptal region by lack of Evans blue in this region. 
Gross slices were photographed with a digital camera (Fujifilm FinePix 2400 Zoom). Morphological changes in 
size, shape and transmural distribution of myocardial infarction were measured using 2,3,5-triphenyltetrazolium 
chloride (TTC) staining (Sigma-Aldrich Chemical Co., St. Louis, MO, USA). Tissue slices were rinsed with a 
cold isotonic saline solution and then incubated at 38 °C for 15-20 min in a phosphate-buffered solution of TTC 
(1% in 0.1 M, pH 7.4) [31,32]. This produced a brick red coloration in the presence of dehydrogenase enzymes 
in intact myocardium whereas infracted regions remained unstained due to the collapse of enzyme activity. After 
photography with a digital camera (Fujifilm FinePix 2400 Zoom, Elmsford, NY, USA), slices of myocardium 
were placed in 10% neutral-buffered formaldehyde to enhance the contrast between stained and unstained 
regions. After 3 days of fixation in formalin and just before paraffin proceeding, myocardial sections were again 
photographed with a video camera (3CCD color video, DXC-390P ExwaveHAD, Sony, New York, NY, USA). 
Infarct size was measured from the tracings of these photographed myocardial slices to a clear acetate sheet and 
the area of each zone was then weighted. The ratio between the two zones (ischemic area and non-ischemic area) 
was determined for each slice. 
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Infarct size measured from the tracings of myocardial slices was calculated by planimetry as a percentage of LV 
mass. 
2.4.  Histopathogical analysis of myocardium 
After 3 days, three or four tissue-blocks were taken from each slice at standardised locations and routinely 
processed for paraffin histology. The tissue blocks from myocardium were cut at 6 µm and each section was 
stained with hematoxylin and eosin (H&E) and Masson trichrome stain. The stained sections were examined at 
magnifications of x25, x100, x200 and x400 to study the distribution of infarction. Photomicrographs were taken 
using a Zeiss photomicroscope (Axioscope 2 plus-Sony 3CCD camera, 1024-768 pixels definition, Thornwood, 
NY, USA). In addition, all tissue-blocks of slice S3 were processed for immunohistochemical staining of desmin 
to investigate more in details cardiac muscle's lesions. Monoclonal antibodies to desmin (clone D33, Biomeda, 
Foster City, CA, USA) were diluted 1/20. 
2.5.  Electron microscopy 
Samples from cardiac tissue (2-3 mm square and 1 mm thick) were taken from anteroseptal and posterior regions 
of slice S2 and were kept in freshly prepared glutaraldehyde buffer fixative. Tissue samples were embedded in 
Epon after fixation in 2% osmium tetroxide, dehydration in ethanol series and substitution by propylene oxide. 
Semi-thin sections (2 µM) were cut, mounted on glass microscope slides and stained with toluidine blue. After 
examination of the semi-thin sections by light microscopy, artifact-free areas were selected for preparation of 
thin sections (90 nm) for electron microscopy. These sections were coated on copper grids, stained with uranyl 
acetate and viewed in a JEOL 1200 EXII transmission electron microscope (JEOL, Tokyo, Japan). For each 
sample, 15-20 micrographs were examined to characterise cardiomyocytes injury. 
2.6.  Biochemical markers dosages (Cardiac myocytes ATP, plasmatic creatine phosphokinase and 
plasmatic troponine T levels) 
The myocardial ATP content was measured by an adaptation of the ATP bioluminescent assay kit (Sigma-
Aldrich diagnostic kit, St. Louis, MO, USA). There is a linear relationship between the relative light intensity 
generated by luciferin-luciferase reaction and the ATP concentration. Samples of cardiac tissue taken from 
anteroseptal and posterior regions of slice S2 were sequentially frozen in liquid nitrogen and then conserved at -
80 °C till ATP dosage. Sample was mechanically disrupted, reduced in powder and then suspended in 700 µl of 
somatic cell ATP releasing reagent. The suspension was then homogenised with a Dounce (10 times), diluted 
with ultra pure water and 10 µl added to 100 µl of ATP assay mix (luciferase, luciferin, MgSO4, EDTA, DTT 
and BSA in a Tricine buffer). For each sample, luminescence in Relative Light Unit (RLU) was determined with 
a luminometer (LUMAC Biocounter M2010). Bradford's protein dosage was performed, and results expressed in 
nmol ATPg-1 of protein. 
Arterial blood samples were taken every 60 min after starting LAD occlusion. Samples were collected in plastic 
tubes containing 1/10 volume of 3.8% trisodium citrate and were centrifuged at 2205 × g for 10 min at 15 °C. 
The supernatant was removed and analysed for plasma creatine phosphokinase (CPK) and troponine T (TnT) 
concentrations. 
2.7.  Ex vivo platelet aggregation study 
The antiplatelet potency of BM-573 was determined according to a previously described method [21]. Briefly, 
blood samples were collected using tubes containing 1:9 citrate (final conc. 0.38%). The platelet-rich plasma 
(PRP) was obtained from the supernatant fraction after centrifugation for 20 min at 90 × g (25 °C). The 
remaining blood was centrifuged at 1200 × g for 10 min (25 °C) and the supernatant gave the platelet-poor 
plasma (PPP). The platelet concentration of PRP was adjusted to 3 × 108 cells ml-1 by dilution with PPP. 
Aggregation tests were performed according to Born's turbidimetric method by means of a four-channel 
aggregometer (bioData Corporation, PAP4). PPP was used to adjust the photometric measurement to the 
minimum optical density. PRP (225 µl) was added in a silanised cuvette and stirred (1100 rev min-1). Platelet 
aggregation was initiated by addition of (5 µl) arachidonic acid (600 µM final) or (1 µl) U-46619 (1 µM final). 
To evaluate platelet aggregation, the maximum increase in light transmission (platelet aggregation amplitude) 
was determined from the aggregation curve 6 min after addition of the inducer. 
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2.8.  Statistical analysis 
All data are expressed as mean ± standard error of the mean (S.E.M.). Changes in ventricular and arterial 
parameters, and offsets for various relationships, were evaluated by a two-way repeated measures analysis of 
variance, with time as the first factor, and intervention (vehicle/BM573) as the second factor. 
When the Snedecor F was significant, multiple comparisons were made with the Scheffe test. Results of 
statistical tests were considered significant for a level of uncertainty of 5% (P < 0.05). Statistical tests were 
performed using the Statistica software (Statsoft Inc, OK, USA). 
3. Results 
3.1. Hemodynamic data 
There was no statistically significant difference between the two groups, at baseline in any of the measured or 
calculated hemodynamic parameters. At baseline, LAD coronary artery blood flow was 42.3 ± 1.6 ml min-1 in 
the vehicle group, and 41.5 ± 2.4 ml min-1 in the BM-573-treated group (NS). 
3.1.1. Effects of acute regional ischemia 
The evolution during myocardial ischemia was statistically comparable in the two groups for all measured or 
calculated hemodynamic parameters. In both groups, LAD coronary artery blood flow immediately dropped to 
zero after application of the surgical clamp. 
While mean aortic pressure remained stable, heart rate increased from 102 ±6 beats min-1 at baseline to 114 ± 9 
beats min-1 at T60 (P = 0.02) and mean aortic flow decreased from 73.2 ± 4.9 ml s-1 at baseline to 62.6 ± 5.8mls-1 
at T60 (P = 0.01) (Fig. 1). 
Applying the WK3 model to the aortic pressure and flow waveforms, we observed that peripheral resistance R2 
significantly (P = 0.01) increased from 1.34 ± 0.17 mmHg s ml-1 to 1.64 ± 0.24 mmHg s ml-1, between baseline 
and T60 (Fig. 2). In the same interval, neither characteristic impedance R1 nor compliance C did significantly 
change. As a consequence, effective arterial elastance Ea, integrating LV afterload, increased from 2.58 ± 0.34 
mmHg ml-1 to 3.44 ± 0.55 mmHg ml-1, between baseline and T60 (P = 0.001). 
As represented in Fig. 3, end-systolic volume Ves varied from 31.8 ±6.2 ml at baseline to 37.1 ±3.6 ml at T60         
(P = 0.09), while end-diastolic volume Ved did not change. However, in the same interval, stroke volume SV and 
ejection fraction EF decreased from 38.9 ± 3.4 ml at baseline to 31.0 ± 1.6 ml at T60 (P = 0.001), and from          
57 ± 4% at baseline to 46 ± 2% at T60 (P = 0.005), respectively. 
While end-systolic elastance Ees remained unchanged, dead volume Vd increased from -27.7 ± 6.6 ml at baseline 
to -13.7 ± 3.9 ml at T60 (P = 0.005) (Fig. 4). In the same interval, the slope of the preload recruitable stroke 
work decreased from 76.7 ±6.6 mmHg to 66.4 ± 5.6 mmHg (P = 0.001), and left ventriculo-arterial coupling 
Ees/Ea from 0.71 ±0.10 to 0.56 ± 0.11 (P = 0.01). 
As illustrated in Fig. 5, stroke work SW and pressure-volume area PVA, respectively decreased from 3900 ± 239 
mmHg ml to 2829 ± 244 mmHg ml (P = 0.001), and from 7033 ± 508 mmHg ml to 5616 ± 606 mmHg ml              
(P = 0.01), between baseline and T60. As a consequence, mechanical efficiency SW/PVA changed, in the same 
time interval, from 0.55 ± 0.04 to 0.50 ± 0.03 (P = 0.04). 
3.1.2. Effects of coronary reperfusion 
The evolution during myocardial reperfusion was statistically comparable in the two groups for all measured or 
calculated hemodynamic parameters. Shortly after removal of the surgical clamp, LAD coronary blood flow was 
measured at 39.6 ± 4.5 ml min-1 in the vehicle group, and at 40.9 ± 3.8 ml min-1 in the BM-573-treated group 
(NS between groups and versus baseline). In either group, it did not significantly change thereafter. 
In both groups, reperfusion induced a further decrease in mean aortic blood flow (from 62.6 ± 10.8 ml s-1 at T60 
to 44.6 ± 6.9 ml s-1 at T300; P<0.001), and an increase in heart rate (from 114 ± 9 beats min-1 at T60 to 140 ± 5 
beats min-1 at T300; P = 0.003), while mean aortic pressure did not significantly change (Fig. 1). 
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Fig. 1: Evolution of mean aortic pressure Pmean, mean aortic flow Qmean, and heart rate HR during myocardial 
ischemia and reperfusion. Ischemia was induced immediately after baseline recordings (TO) by occluding the 
LAD coronary artery, which was reperfused after T60 measurements. *P<0.05 vs. T0; **P<0.01 vs. T0; 
***P<0.001 vs. T0; ## P<0.01 vs. T60; ### P< 0.001 vs. T60. 
 
 
Applying the WK3 model to the aortic pressure and flow waveforms, we observed that, in both groups, 
characteristic impedance and compliance remained unchanged, while peripheral resistances R2 increased 
significantly (P = 0.02) from 1.64 ± 0.24 mmHg s ml-1 at T60 to 2.28 ± 0.38 mmHg s ml-1 at T300 (Fig. 2). As a 
consequence, effective arterial elastance increased (P = 0.001) similarly in both groups, from 3.44 ± 0.55 mmHg 
ml-1 at T60 to 5.36 ± 1.09 mmHg ml-1 at T300. 
While end-diastolic volume remained unchanged in both groups, coronary reperfusion induced a severe decrease 
(P < 0.001 ) in stroke volume SV and in ejection fraction, from 31.0 ± 1.6 ml at T60 to 20.9 ± 2.2 ml at T300, 
and from 46 ± 2% at T60 to 28 ± 3% at T300, respectively (Fig. 3). 
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As depicted in Fig. 4, while end-systolic elastance remained statistically unchanged in both groups during 
reperfusion, dead volume Vd further increased (P< 0.001) from -13.7 ± 3.9 ml at T60 to 9.8 ± 7.7 ml at T300, 
while left ventriculo-arterial coupling Ees/Ea decreased from 0.56 ± 0.11 to 0.43 ± 0.05 (P = 0.01) in the same 
interval. 
During reperfusion, stroke work and pressure-volume area decreased from 2829 ± 244 mmHg ml to 2169 ± 192 
mmHg ml (P = 0.02), and from 5616 ± 606 mmHg ml to 4103 ± 563 mmHg ml (P = 0.005), respectively, while 
mechanical efficiency was statistically unchanged (Fig. 5). 
3.2.  Macroscopy: risk area and infarct size 
Areas at risk in the vehicle-treated group and BM-573-treated group were not different from each other. The area 
at risk was 33.2 ± 3.4% of left ventricle (LV). In non-treated and BM-573-treated groups, the infarct size, 
expressed as the percentage of left ventricle was 33.6 ±4.1% and 27.3 ± 2.6% of LV, respectively, or 82% of the 
area at risk in the BM-573-treated group (Fig. 6A and B). Although the infarct size evidenced by TTC staining 
was slightly smaller in the treated group, this difference was however not statistically significant (P = 0.32). 
 
Fig. 2: Evolution of three-element windkessel model parameters during myocardial ischemia and reperfusion. 
Ischemia was induced immediately after baseline recordings (TO) by occluding the LAD coronary artery, which 
was reperfused after T60 measurements. R\, characteristic impedance; R2, peripheral resistance; C, compliance; 
Ea, effective arterial elastance. *P < 0.05 vs. T0; **P < 0.01 vs. T0; ***P < 0.001 vs. T0; # P < 0.05 vs. T60; ## 
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Fig. 2: (Continued). 
 
3.3.  Histopathology 
All hearts from control and BM-573-treated groups were examined by light microscopy. Histopathological 
examination revealed that main ischemic changes were observed in the anterior left ventricle, corresponding to 
the area supplied by the LAD coronary artery. Whatever the treatment (vehicle or BM-573), infarcted 
myocardium displayed altered muscle cells showing a waviness aspect which express prominent myofibrillar 
contraction bands, anisokaryosis, and accumulation of interstitially infiltrated inflammatory cells as neutrophils 
and lymphocytes (Fig. 7A). These characteristics also associated with extensive hemorrhage region suggest that 
these cells probably reached the stage of necrosis. Immunohistochemical detection of desmin revealed, mainly in 
the anteroseptal region, clear zones of patchy necrosis (Fig. 7D) and blurred zones where it was difficult to 
clearly delineate necrotic zone from healthy myocardium due to motley aspect (Fig. 7C). Area not supplied by 
the LAD artery (posterior region) showed normal morphology (Fig. 7B). 
3.4.  Electron microscopy 
Transmission electron microscopy of representative samples was used to characterise myocardium damage and 
to give a definitive diagnosis. It appeared that whatever the treatment with vehicle or BM-573 (10 mg kg-1 h-1), 
all samples taken in posterior (control) region had the ultrastructural features of healthy myocardium. Indeed, 
sar-colemma was intact, nuclear chromatin, nucleus and mitochondria were normal (Fig. 8A and B). In vehicle-
treated group, all samples from the anteroseptal region (ischemic region) presented irreversible injury 
characterised by mitochondrial swelling, mitochondria exhibiting amorphous matrix flocculent densities (AMD) 
or "woolly densities", marked nuclear changes with chromatin clumping, damage to the sarcolemma and 
breakdown of myofibrillar organisation (Fig. 8C and D). Samples taken in the anteroseptal region from BM-573-
treated group showed similar ultrastructural features as those observed in the same region from samples of 
vehicle-treated group (Fig. 8E and F). 
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Fig. 3: Evolution of end-systolic volume Ves, end-diastolic volume Ved, stroke volume SV, and ejection fraction 
EF during myocardial ischemia and reperfusion. Ischemia was induced immediately after baseline recordings 
(T0) by occluding the LAD coronary artery, which was reperfused after T60 measurements. * P<0.05 vs. T0; ** 
P<0.01 vs. T0; *** P<0.001 vs. T0; ### P< 0.001 vs. T60. 
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Fig. 4: Evolution of end-systolic elastance Ees, dead volume Vd, slope of PRSW relationship, and ventriculo-
arterial coupling Ees/Ea during myocardial ischemia and reperfusion. Ischemia was induced immediately after 
baseline recordings (TO) by occluding the LAD coronary artery, which was reperfused after T60 measurements. 
PRSW, preload recruitable stroke work. * P<0.05 vs. T0; ** P<0.01 VS. T0; *** P<0.001 VS. T0; # P<0.05 vs. 
T60; ### P< 0.001 vs. T60. 
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Fig. 5: Evolution of stroke work SW, pressure-volume area PVA, and mechanical efficiency SW/PVA during 
myocardial ischemia and reperfusion. Ischemia was induced immediately after baseline recordings (TO) by 
occluding the LAD coronary artery, which was reperfused after T60 measurements. * P<0.05 vs. T0; ** P<0.01 
vs. T0; *** P<0.001 vs. T0; # P<0.05 vs. T60; ## P<0.01 vs. T60. 
 
3.5.  Biochemical data 
ATP content was measured in myocardium from control and BM-573-treated animals. Two samples were 
judiciously taken from slice two of four hearts in each group, one in the anteroseptal region and one in the 
posterior region stained by TTC (Fig. 9). In both groups, a significant myocardial ATP decrease was observed in 
the anteroseptal region compared with the healthy region (posterior) (23540 ± 3328 nmol g-1 versus 1384 ± 672 
nmol g-1 of protein in BM-573-treated pigs and 9844 ± 3880 nmol g-1 versus 1330 ± 367 nmol g-1 of protein in 
vehicle-treated pigs). Reperfusion and BM-573 administered during reperfusion failed to prevent drop of ATP or 
restore the ATP concentration in the anteroseptal region. 
A marked elevation of plasma CPK and TnT concentrations were observed in both groups after reperfusion. Data 
on the graph (Fig. 10A and B) show that BM-573 failed to reduce CPK and TnT plasmatic concentrations. 
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3.6. Aggregometric data 
Platelet aggregation amplitude was evaluated in BM-573 and vehicle groups. In both groups, ex vivo platelet 
aggregation induced by arachidonic acid or by U-44619 was complete and irreversible at TO. Intravenous 
infusion (10 mg kg-1 h-1) of BM-573 resulted in a complete inhibition of platelet aggregation provoked by 
arachidonic acid or by U-44619 at T60, T120, T240 and T300. In the vehicle group, platelet aggregation induced 
by either inducer remained complete and irreversible throughout the experiment (Fig. 11). 
4. Discussion 
Occlusion of the LAD coronary artery induced a rightward shift of the end-systolic pressure-volume relationship, 
a decrease in ejection fraction, in cardiac output, in the slope of the SW-EDV relationship, and in mechanical 
efficiency. All these changes were consistent with an impairment in cardiac performance and efficiency, and 
matched previous experimental studies on regional myocardial ischemia [33,34]. Furthermore, LV afterload was 
increased, as evidenced by an augmentation in effective arterial elastance, mainly due to peripheral 
vasoconstriction, and induced left ventriculo-arterial mismatch. BM-573-treated animals displayed changes in 
hemodynamic parameters that were similar to those observed in the vehicle group. 
In both groups, coronary reperfusion was associated with a further decrease in cardiac performance, as expressed 
by a drop in cardiac output and in ejection fraction, and a further ESPVR rightward shift. Facing further 
increased arterial elastance, ventriculo-arterial coupling continued to deteriorate. The impairment in 
hemodynamic parameters associated with coronary reperfusion was not prevented by BM-573 infusion. 
Myocardial infarction was outlined by incubating the heart slices in a buffered solution of TTC, which is reduced 
to a brick red formazan by dehydrogenase enzymes contained in healthy myocardium. Following necrosis, lack 
of these enzymes results as an unstained area. After 60 min of occlusion followed by 4 h of reperfusion, the 
percent of infarct area was similar to that of the area at risk, and histologic changes, mainly located in the 
anteroseptal region, were not ameliorated by BM-573 administration. Furthermore, increased plasma 
concentrations of CPK and TnT, indicators of tissue necrosis, were not reduced and similar drops of ATP level, 
measured in anteroseptal region versus posterior region, were observed in the vehicle group and in the BM-573-
treated group. 
Thromboxane A2 is a major prostanoid in the cardiovascular system, whose biological properties include platelet 
aggregation, constriction of vascular smooth muscles, and leukocyte chemotaxis [35]. In the vascular system, 
TXA2 is produced mainly by platelets, but it has also been found to be produced by cardiomyocytes, suggesting 
some direct role in the heart. Moreover, its synthesis is significantly increased during ischemia-reperfusion 
[13,14,36], and its rhodopsin-type receptor, TP, has been reported to be expressed on cardiomyocytes [37]. 
Several studies have reported the beneficial effects of TXA2 synthase inhibitors on cardiac ischemia-reperfusion 
[17,38-40]. Such beneficial effects were, at least partly, attributed to enhanced generation of PGI2 derived from 
increased availability of its precursor, resulting in inhibition of neutrophil adhesion to endothelial cells [17,39]. 
In contrast, studies evaluating the effects of TXA2 antagonists during myocardial ischemia-reperfusion yielded 
contradictory results. Indeed, beneficial effects of TP antagonists in cardiac ischemia-reperfusion have been 
reported in several studies in dogs [15], in cats [16,41,42] and in rats [43]. However, others have not observed 
such a protective effect [17,18]. 
Recently, Ge et al. [18] compared two TXA2 receptor antagonists, KT2-962 and daltroban (BM 13.505) in an 
open-chest dog model of myocardial ischemia-reperfusion injury. They found that administration of KT2-962, 
but not daltroban, significantly reduced the incidence of ventricular fibrillation during the ischemic period and 
the myocardial area at risk by about 40%. They subsequently showed, using electron spin resonance 
spectroscopy, that KT2-962 inhibited the formation of hydroxyl radicals, whereas daltroban had no effect. These 
authors concluded that the beneficial effects of KT2-962 was probably due to its direct free radical scavenging 
properties rather than its ability to block TXA2 receptors. 
Among several factors that may contribute to such discrepancy, are differences in animal species, degree of 
collateral blood flow, duration of ischemia, timing of drug administration, drug delivery method, and different 
end-points of cardio protection (infarct size, myocardial function, endothelial function or arrhythmias). Another 
factor may result from the fact that some TP antagonists, but not others, cross-act on other prostanoid receptors, 
such as EP3, through which PGE2 was reported to exert protective effects on cardiac ischemia-reperfusion injury 
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[44]. 
Concerning animal species, numerous studies have used a canine or a feline model. However, the use of dogs or 
cats in the setting of myocardial ischemia-reperfusion has some important pathophysiological drawbacks, such 
as the often substantial and unpredictable coronary collateral blood flow in these species. Pigs were used in this 
study because of the similarity between hearts from pigs and humans concerning the physiological properties, 
the anatomical distribution of coronary arteries, the lack of collateral circulation and the heart-to-body weight 
ratio [45,46]. 
Duration of ischemia in another factor of importance. In pigs, Miyazaki et al. [47] studied the effects of various 
duration (20, 30, 60 and 120 min) of LAD coronary artery occlusion followed by 8 h of reperfusion. With an 
occlusion time of 60 min, they found results similar to ours. Actually, they showed a transmural infarct despite 
reperfusion after 60 min of occlusion. They observed that the infarct area after reperfusion increased 
significantly with the duration of the occlusion and reached 80 ± 9% of the risk area when the LAD was 
occluded during 60 min. Other studies demonstrated that 1 h of ischemia (without reperfusion) was sufficient to 
produce severe myocardial lesions, because of absence of collateral circulation in pig heart [48]. 
After 4 h of reperfusion and despite associated BM-573 infusion, major structural changes were caused in 
myocytes. Thus, myocardial ATP content did not recover and electron microscopy showed irreversible injury 
notably characterised by appearance of mitochondrial amorphous matrix (flocculent) densities (AMD) which are 
complexes of insoluble proteins and lipid resulting from destruction of mitochondrial membranes [49,50]. 
 
Fig. 6: Photographs of gross slices of heart after TTC staining from vehicle-treated animals suffering from 1 h 
of ischemia and 4 h of reperfusion (A), and from BM-573-treated animals suffering from 1 h of ischemia and 4 h 
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Fig. 7: Light micrographs of myocardial necrosis occurring during ischemia (1 h) and 4 h of reperfusion, 
without and with BM-573 treatment. (A) Wavy aspect of the necrotic fibres and accumulation of interstitially 
infiltrated inflammatory cells in anteroseptal region of control pig (Masson's trichrome stain, original 
magnification × 200). (B-D) Immunohistological staining of desmin. Normal myocardial muscle in the posterior 
region (B, original magnification × 400). Motley aspect of myocardium in the anteroseptal region of BM-573-
treated pig where separation between necrotic and viable myocardium is not obvious (C, original magnification 
× 200). Patchy necrosis is shown at the lower right portion of the photomicrograph (arrow) taken in 
anteroseptal region of control pig (D, original magnification × 100). 
 
 
In this study, BM-573 was administered intravenously at the dose of 10 mg kg-1 h-1. This was sufficient to 
prevent platelet aggregation induced by arachidonic acid suggesting that the thromboxane receptors are blocked. 
Moreover, in a previous study, our team demonstrated that this regimen was also responsible for a complete 
inhibition of the thromboxane synthase revealed by a prevention of TXA2 overproduction. These results confirm 
the efficacy of BM-573 as a potent TXA2 receptor antagonist [20,21], indicating that, although the drug was 
ineffective in this ischemia-reperfusion model, it remains active as thromboxane modulator. 
However, it could be argued that this route of administration may be insufficient during myocardial ischemia, 
essentially because the drug did not reach the ischemic area in the absence of collateral circulation. Further, 
intravenous administration usually requires a large dose in order to achieve adequate concentration in the 
ischemic -reperfused area. Accordingly, a substantial amount of the substance reaches the non-ischemic area 
with possible risk of negative impact on myocardial function. In addition, systemic effects can also be observed, 
for example by modifying systemic vascular resistances that in turn cause changes in cardiac afterload and 
subsequently in the infarct size. 
Other possible routes for drug administration include antegrade arterial intracoronary perfusion, which may 
however interfere with coronary blood flow, and coronary venous retroperfusion. Ryden et al. [51] have shown 
that coronary venous retroperfusion led to the accumulation of substantial amounts of drug specifically in the 
ischemic parts of the myocardium, while concentrations in plasma and in non-ischemic myocardium remained 
low. We chose to use the intravenous route because it is closer to the clinical setting. Further, we have previously 
shown that BM-573 has no direct effect on cardiac function nor on vascular afterload [20]. However, it is 
possible that administration of BM-573 through the coronary venous retroperfusion route would have yielded 
different results. 
In a recent study, Xiao et al. [52] assessed the roles of prostaglandin I2 and TXA2 in cardiac ischemia-reperfusion 
injury, using mice lacking their respective receptors. While they demonstrated that PGI2, produced endogenously 
during myocardial ischemia-reperfusion, exerts a protective effect on cardiomyocytes, these authors concluded 
that TXA2 has little role in cardiac ischemia-reperfusion injury. 
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Fig. 8: Ultrastructure of normal myocardium (posterior region) with normal mitochondria, nucleus presenting 
normal chromatin (A) and intact sarcolemma (B). Irreversibly injured myocardium with mitochondrial swelling 
(C, D and F) presenting amorphous matrix densities (AMD), distortion of sarcomeres and contraction bands   
(D and E), and chromatin clumping (E). A (×10,000) and B (×8000) were taken from samples of posterior 
region from a vehicle-treated pig. (C) (×20,000) and (D) (×12,000) were taken from samples of anteroseptal 
region from a vehicle-treated pig. (E) (×6000) and (F) (×10,000) were taken from samples of anteroseptal 
region from a BM-573-treated pig. 
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Fig. 9: ATP content (nanomoles per gram of protein) of heart slice two from control animals (n = 4) and BM-
573-treated animals (n = 4) (*** P < 0.001 and * P<0.5). 
 
 
Fig. 10: Effect of BM-573 (A) on plasma creatine phosphokinase (CPK) concentration in international unit 
(IU1-1) and (B) on plasma troponine T (TnT) concentration (µgl-1). 
 
However, the actions of TXA2 on platelets and vasculature should contribute to the pathogenesis of 
atherosclerosis and/or vasospasm, prerequisites for coronary artery disease. Recently, we showed, in a porcine 
model, that BM-573 was able to prevent the formation of an occlusive thrombus in FeCl3 -induced endothelium-
damaged LAD coronary artery, and the development of subsequent myocardial infarction [20]. This FeCl3 
model, as compared to direct occlusion, mimics more closely the development of an occlusive thrombus at the 
site of a ruptured atherosclerotic plaque in humans, but cannot be used to study myocardial ischemia-reperfusion 
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as it triggers irreversible endothelial lesions. 
Fig. 11: Time course of platelet aggregation amplitude induced by arachidonic acid in the vehicle group (black 
columns) and in the BM-573 group (empty columns). 
 
Conclusion 
In conclusion, this study showed that BM-573, a combined TXA2 synthesis inhibitor and receptor antagonist, 
failed, at macroscopic, histopathological, and ultrastructural levels, to reduce the extension of myocardial tissue 
damage in a porcine model of ischemia-reperfusion. Biochemical and hemodynamic analysis confirmed the 
installation of a severe myocardial infarction despite BM-573 administration. 
However, as one of the most important mediator triggering platelet aggregation, TXA2 participates in coronary 
artery thrombus formation which potentially leads to acute myocardial infarction and severe tissue damage. 
Consequently, prevention of myocardial infarction remains a major indication for the use of a thromboxane 
modulator, such as BM-573, as demonstrated by our team in a previous study [20]. This indeed supports the 
mode of action and the efficacy of aspirin in prevention of acute thrombotic events. 
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